Üriner Sistem Semptomları Olan Multipl Sklerozlu Hastalarda Üriner Sinir Büyüme Faktörü Düzeyleri

Year 2021, Volume: 16 Issue: 2, 273 - 278, 07.07.2021

Muhammed Seyithanoğlu Yılmaz İnanç Songül Bavli

https://doi.org/10.17517/ksutfd.793595

Abstract

Amaç: MS hastalarında idrar sinir büyüme faktörünün (NGF) duyarlılığını ve özgüllüğünü detrüsör aşırı aktivitesinin belirteçleri olarak tahmin etmek.
Materyal ve Metod: Multipl Skleroz tanısı ile takip edilen üriner sistem semptomları olan 20 gönüllü hasta ve Multipl Skleroz tanısı olan ancak üriner sistem semptomları olmayan 29 gönüllü hasta çalışmaya dahil edildi. Kişilerden kapsamlı bir anamnez ve spot idrar örnekleri alındı. Benzer yaş ve cinsiyet dağılımına sahip 27 sağlıklı gönüllü NGF düzeyleri açısından karşılaştırma yapmak üzere dahil edildi ve spot idrar örnekleri alındı.
Bulgular: İdrar NGF düzeyleri ve NGF/idrar Kreatinin oranları üriner semptomları bulunan MS hasta grubunda üriner semptomları bulunmayan hasta grubuna göre istatistiki olarak anlamlı olmayan şekilde daha düşüktü, üriner semptomları olmayan hasta grubunda da control grubuna göre istatistiki olarak anlamlılık içermeyen düşüklük gözlendi (p: 0,114 ve 0,833)
Sonuç: Multipl sklerozlu hastalarda idrar nörotrofinleri detrüsör aşırı aktivitesini teşhis etmek için kullanılabilir.

Keywords

Multipl skleroz, sinir büyüme faktörü, idrar yolu disfonksiyonu

Urinary Nerve Growth Factor Levels In Multiple Sclerosis Patients With Urinary System Symptoms

Abstract

Aim: To estimate the sensitivity and specificity of the serum and urinary nerve growth factor (NGF) in MS patients as markers of detrusor overactivity.
Materials and Methods: 20 volunteers who were diagnosed with MS and who had urinary tract symptoms and 29 volunteers who were diagnosed with MS however who did not have urinary tract symptoms were included in the study. A comprehensive anamnesis and spot urine samples were obtained from the subjects. Twenty seven healthy volunteers with similar age and gender distribution were included for making a comparison with regard to NGF levels and spot urine samples were obtained.
Results: Urinary NGF levels and NGF/urinary creatinine ratios were found lower in the group composed of MS patients who had urinary symptoms compared to the group composed of MS patients who did not have urinary symptoms but the difference was not statistically significant. These parameters were found lower in patient group who did not have urinary symptoms compared to control group however the difference was not statistically significant (p: 0,114 and 0,833)
Conclusions: urinary neurotrophins in patients with multiple sclerosis can be used to diagnose detrusor overactivity.

Keywords

Multiple sclerosis, nerve growth factor, urinary tract dysfunction

References

• 1. Siva A.The spectrum of multiple sclerosis and treatment decisions. Clin Neurol Neurosurg 2006;108:333-338.
• 2. Dobson, R., & Giovannoni, G. (2019). Multiple sclerosis–a review. European journal of neurology, 26(1), 27-40.
• 3. Keramat Kar, M., Whitehead, L., & Smith, C. M. Characteristics and correlates of coping with multiple sclerosis: a systematic review. Disability and rehabilitation, 2019; 41(3): 250-264.
• 4. Azami, M., Yekta Kooshali, M. H., Shohani, M., Khorshidi, A., & Mahmudi, L. Epidemiology of multiple sclerosis in Iran: A systematic review and meta-analysis. PloS one, 2019; 14(4).
• 5. Leboeuf L, Gousse AE. Multiplsclerosis. In(Ed. Corcos J, Schick E)Textbook of the Neurogenic Bladder Adults and Children 2005; 275-292,Maritz Dunitz, London.
• 6. Taylor RS. Rehabilitation of persons with multipl sclerosis. In (Ed. Braddom RL)Physical Medicine and Rehabilitation Saunders, Philadelphia 2000; 1177-1190.
• 7. Özgül A, Alaca R. Rehabilitation in multiple sclerosis. In (Ed. Özcan O, Arpacıoğlu O, Turan B) Neurorehabilitation 2000; 183-205, Güneş and Nobel Medical Bookstores Turkey.
• 8. Araki I, Matsui M, Ozawa K, Takeda M, Kuno S. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol 2003;169:1384-1387.
• 9. Bhide AA, Cartwright R, Khullar V, Digesu GA. Biomarkers in overactive bladder. Int Urogynecol J 2013;24:1065–1072.
• 10. Cruz F, Tubaro A. Future assessments of overactive bladder. Eur Urol Rev 2012;7:36–41.
• 11. Faydacı G, Tarhan F, Gül AE, Erbay E, Kuyumcuoğlu U. The role of nevre growth factor receptor in bladder outlet obstruction. Turkish Urol Journal 2004;30:72-79
• 12. Rocco M. L, Soligo M., Manni L., Aloe L. Nerve growth factor: early studies and recent clinical trials. Current neuropharmacology 2018; 16(10), 1455-1465.
• 13. Skaper SD. Thebiology of neurotrophins, signalling pathways, and functional peptid emimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets 2008;7:46–62.
• 14. Zhu ZW, Friess H, Wang L, Bogardus T, Korc M, et al. Nevre growth factor exerts differentia leffects on the growth of human pancreatic cancer cells. Clin Cancer Res 2001;7:105-112. 15. Berker E. Neuropathic pain and physiopathological mechanisms. Turkish physiotheraphy Rehab Journal 2005; 51:1-5.
• 16. Huang F , Dong X , Zhang L , Zhang X , Zhao D ,et al. Neuroprotectiveeffects of NGF combined with GM1 on DRG and spinal cord neurons sciatic nevre injured rats. J Neurosci 2010;27:160-169.
• 17. Işık A. Physiopathology of pain. Turkish Phys Medicine Rehab Journal 2005;51:B8-B13
• 18. Hu VY, Zvara P, Dattilio A, Redman TL, Allen SJ, et al. Decrease in bladder overactivity with REN1820 in rats with cyclophosphamide induced cystitis. J Urol 2005;173:1016–1021.
• 19. Pezet S, McMahon SB. Neurotrophins: Mediators and modulators of pain. Annu Rev Neurosci 2006;29:507–538.
• 20. Aloe, L., Rocco, M. L., Balzamino, B. O., & Micera, A. Nerve growth factor: role in growth, differentiation and controlling cancer cell development. Journal of Experimental & Clinical Cancer Research,2016; 35(1), 116.
• 21. Lowe EM, An and P, Terenghi G, Williams-Chestnut RE, Sinicropi DV, et al.Increased nevre growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol 1997; 79: 572–577
• 22. Tuttle JB, Steers WD, Albo M, Nataluk E. Neuralin putregulatest issue NGF and growth of the adult urinary bladder. J Auton Nerv Syst 1994; 49: 147–158
• 23. Dupont MC, Spitsbergen JM, Kim KB, Tuttle JB, Steers WD.Histological and neurotrophic changes triggered by varying models of bladder inflammation. J Urol 2001; 166 : 1111–1118
• 24. Skaper S.D. Nerve growth factor: a neuroimmune cross talk mediator for all seasons. Immunology, 2017; 151(1):1-15.
• 25. Bonini S, Lambiase A, Bonini S, Levi-Schaffer F, AloeL.Nerve growth factor: an important molecule in allergic inflammation andt issue remodeling. Int Arch Allergy Immunol 1999;118:159–162.
• 26. Liu HT, Chancellor MB, Kuo HC. Urinary nevre growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. EurUrol 2009;56:700–706.
• 27. Antunes-Lopes T, Carvalho-Barros S, Cruz CD, Cruz F, Martins-Silva C. Biomarkers in over active bladder: A new objective and noninvasive tool? AdvUrol 2011;2011:382-431.
• 28. Lindner MD, Gordon DD. Increased levels of truncated nevre growth factor receptor in urine of mildly demented patients with Alzheimer’sdisease. ArchNeurol 1993; 50: 1054–1060
• 29. Liu HT, Chen CY, Kuo HC. Urinary nevre growth factor levels in overactive bladder syndrome and lower urinary tract disorders. J FormosMedAssoc 2010;109:862–878
• 30. Oktar T, Kocak T, Oner-Iyidogan Y, Erdem S, Seyithanoglu M, et al. Urinary nevre growth factor in children with overactive bladder: a promising, noninvasive and objective biomarker.J Pediatr Urol 2013;9:617-621
• 31. Marrie R, Cutter G, Tyry T, et al. Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology. 2007;68:1971–8
• 32. Cattaneo A, Calissano P. Nerve growth factor andAlzheimer's disease: newfacts for an old hypothesis.MolNeurobiol 2012;46:588–604.
• 33. Zhu L, Pan QX, Zhang XJ, YM X, Chu YJ, et al. Protective effects of matrine on experimental autoimmune encephalomyelitis via regulation of Pro NGF and NGF signaling. Exp Mol Pathol 2016;100:337–343.
• 34. Salgado AJ, Sousa JC, Costa BM, Pires AO, Mateus-Pinheiro A, et al. Mesenchymal stemcells secretome as a modulator of the neurogenicniche: basic insights and therapeutic opportunities. Front Cell Neurosci 2015;9:249.
• 35. Micera A, Properzi F, Triaca V, Aloe L. Nerve growth factor antibody exacerbates neuropathological signs of experimental allergic encephalomyelitis in adult Lewisrats J. Neuroimmunol 2000; 104 (2):116-123
• 36. Triaca V, P. Tirassa, L. Aloe. Presence of nevre growth factor and TrkA expression in the SVZ of EAE rats: evidence for a possible functional significance. Exp. Neurol 2005;191(1):53-64
• 37. Acosta CM, Cortes C, MacPhee H, Namaka MP. Exploring the role of nevre growth factor in multiple sclerosis: implications in myelin repair. CNS Neurol. Disord. Drug Targets 2013; 12 (8):1242-1256
• 38. Gold, R., Linington, C., Lassmann, H. Under standing pathogenesis and therapy of multiple sclerosis via animalmodels: 70 years of merits and culprits in experimental autoimmun eencephalomyelitis research.Brain 2006;129:1953–1971.
• 39. Mo, L., Yang, Z., Zhang, A., Li, X. There pair of the injured adult rat hippocampus with NT-3-chitosan carriers. Biomaterials 2010;31:2184–2192.
• 40. Yan Q, Elliott J, Snider W. D. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature 1992; 360:753–755.
• 41. Qu Z, Zheng N, Zhang Y, Zhang L, Liu J, et al..Preventing the BDNF and NGF loss involved in the effects of corneliridoid glycoside on attenuation of experimental autoimmune encephalomyelitis in mice. NeurolRes 2016;38(9):831-837.